Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
2013
|
| _version_ | 1797085508179853312 |
|---|---|
| author | Rea, D Gray, R Bowden, S Handley, K Earl, H Poole, C Bates, T Dewar, J Raytor, Z Lee, M |
| author_facet | Rea, D Gray, R Bowden, S Handley, K Earl, H Poole, C Bates, T Dewar, J Raytor, Z Lee, M |
| author_sort | Rea, D |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T02:09:45Z |
| format | Conference item |
| id | oxford-uuid:a036a469-47fa-4e6d-adb6-f7e8f26e55a7 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T02:09:45Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:a036a469-47fa-4e6d-adb6-f7e8f26e55a72022-03-27T02:03:53ZOverall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancerConference itemhttp://purl.org/coar/resource_type/c_5794uuid:a036a469-47fa-4e6d-adb6-f7e8f26e55a7Symplectic Elements at Oxford2013Rea, DGray, RBowden, SHandley, KEarl, HPoole, CBates, TDewar, JRaytor, ZLee, M |
| spellingShingle | Rea, D Gray, R Bowden, S Handley, K Earl, H Poole, C Bates, T Dewar, J Raytor, Z Lee, M Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer |
| title | Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer |
| title_full | Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer |
| title_fullStr | Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer |
| title_full_unstemmed | Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer |
| title_short | Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer |
| title_sort | overall and subgroup findings of the attom trial a randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with er positive or er untested early breast cancer |
| work_keys_str_mv | AT read overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT grayr overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT bowdens overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT handleyk overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT earlh overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT poolec overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT batest overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT dewarj overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT raytorz overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer AT leem overallandsubgroupfindingsoftheattomtrialarandomisedcomparisonofcontinuingadjuvanttamoxifento10yearscomparedtostoppingafter5yearsin6953womenwitherpositiveoreruntestedearlybreastcancer |